相关实验视频

Updated: Jun 1, 2025

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

纳米化非病毒基因疗法逆转了由PBRM1缺陷驱动的衰老重编程,以抑制iCCA的进展

Xiwen Wu^1,2, Yi Zhang^1,3, Yuan Ding¹

¹Department of Hepatic Surgery, Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|January 17, 2025

概括

聚蛋白-1 (PBRM1) 在肝内胆管癌 (iCCA) 中降低调节,促进瘤生长. 通过纳米药物恢复PBRM1表达或抑制ERK1/2信号,可以阻止iCCA的进展.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
基因规则基因规则

背景情况:

聚基-1 (PBRM1) 是一个关键的转录调节器,与各种癌症有关.
它在肝内胆管癌 (iCCA) 中的特定功能和调节机制在很大程度上仍未被定义.
了解PBRM1的作用对于开发新的iCCA治疗策略至关重要.

研究的目的:

阐明PBRM1在iCCA病原和进展中的作用.
研究PBRM1调节iCCA的基础分子机制.
开发和评估基于纳米医学的基因疗法,用于针对PBRM1表达的iCCA.

主要方法:

在iCCA组织中分析PBRM1表达水平和与临床病理特征的相关性.
在体内研究使用基因疗法纳米药来调节iCCA模型中的PBRM1表达.
研究ERK1/2信号通路,p16,p53/p21表达和细胞衰老.
使用U0126.6进行ERK1/2信号的药理抑制.

主要成果:

在iCCA中,PBRM1表达显著下调,与侵袭性疾病和不良预后相关.
低调PBRM1激活ERK1/2通路,减少衰老标志物 (p16,p53/p21) 并促进iCCA的进展.
纳米药物介导的PBRM1上调有效地抑制了iCCA瘤的生长.
用U0126抑制ERK1/2信号传递通过调节PBRM1-ERK1/2-细胞衰老轴来逆转iCCA进展.

结论:

在iCCA中,PBRM1充当瘤抑制剂,其减少的表达是疾病进展的关键驱动因素.
PBRM1-ERK1/2-细胞衰老途径代表了iCCA.的新治疗标.
针对PBRM1和ERK1/2抑制的基因疗法纳米药物显示出iCCA治疗的显著治疗潜力.

关键词:

在ERK1/2中.这就是PBRM1的原因.基因治疗的基因疗法在肝脏内发生的胆固醇癌 (cholangiocarcinoma).纳米医药是一种纳米医学.衰老重编程可以重编程.

更多相关视频

Simple Generation of a High Yield Culture of Induced Neurons from Human Adult Skin Fibroblasts

Simple Generation of a High Yield Culture of Induced Neurons from Human Adult Skin Fibroblasts

Published on: February 5, 2018

Evaluation of Injury-induced Senescence and In Vivo Reprogramming in the Skeletal Muscle

Evaluation of Injury-induced Senescence and In Vivo Reprogramming in the Skeletal Muscle

Published on: October 26, 2017

相关概念视频

Somatic to iPS Cell Reprogramming

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Methods of Nuclear Reprogramming

Methods of Nuclear Reprogramming

Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...